Ace Pharmaceuticals has been acquired by Gilde Buy Out Partners, Gilde Healthcare and Quadrum Capital

Ace Pharmaceuticals BV has been acquired by Gilde Buy Out Partners, Gilde Healthcare, Quadrum Capital and the management team.

Ace Pharmaceuticals is a leading pharmaceutical company in the niche of medical need products, and is based in Zeewolde, the Netherlands. As an independent company, Ace focuses on the development, production and distribution of licensed and unlicensed medicines. With its activities, Ace meets an essential social need: making and keeping scarce medication available for people for whom it is essential. It does so by actively collaborating with relevant stakeholders, including patient associations, doctors and governmental institutions. Since January 2020, Ace has also been supplying pharmaceutical compounding products to pharmacies in the Netherlands through its business unit Ace Compounding.

Oaklins’ debt advisory team in the Netherlands acted as advisor to the consortium and assisted in establishing a financing package aligned with the current business profile and future growth ambitions.

Service

Funding, debt advisory & ECM

Parties

“The COVID-19 pandemic has clearly highlighted the challenges and gaps in our industry in Europe. It makes our mission to make scarce medicines available more important than ever. We want to respond to this situation strongly by growing organically as well as through acquisitions in Europe. With the capital, the know-how and the broad (international) network of Gilde Buy Out Partners, Gilde Healthcare, and our existing investor Quadrum Capital, we can achieve this in both a socially responsible as well as financially sound manner.”

Jan Willem Popma

Director, Ace Pharmaceuticals BV

Talk to the deal team

Bas Stoetzer

Partner

Amsterdam, Netherlands
Oaklins Netherlands

View profile Get in touch

Niels Vermuë

Associate Director

Amsterdam, Netherlands
Oaklins Netherlands

View profile Get in touch

Related deals

Bluegem Capital Partners and AREV Partners have acquired 100% of Groupe Pinard

Private Equity | Consumer & Retail | Other Industries

Bluegem Capital Partners and AREV Partners have acquired 100% of Groupe Pinard

Bluegem Capital Partners and AREV Partners have successfully completed the acquisition of the prestigious Groupe Pinard from IK Partners.

Learn more

Lumiforte partners with Kartesia to propel global growth and innovation

Private Equity | Agriculture | Other Industries

Lumiforte partners with Kartesia to propel global growth and innovation

Lumiforte, a global leader in innovative smart coatings for greenhouse horticulture, sports line-marking and other functional coatings for agriculture and industry, is excited to announce an investment from Kartesia, a European specialist in capital solutions for small and medium-sized companies. Horticoop, a longstanding shareholder of Lumiforte and a key player in the horticultural industry through its investment cooperative, continues to remain a shareholder.

Learn more

PanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production

Healthcare

PanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production

PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.

Learn more